Clinical Trial

A Study of Tarlatamab for People With Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-08-01; most recent amendment 2026-06-16.
Trial Details
NCT Number NCT07111507
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Amgen
Conditions Metastatic Prostate Cancer
Enrollment 32 participants
Start Date 2025-07-31
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17